2022 American Transplant Congress
M1 Macrophage Polarization in Antibody-Mediated Rejection After Renal Transplantation and the Intervention Study of Iguratimod
*Purpose: After kidney transplantation, Antibody Mediated Rejection (ABMR) is the main factor affecting the long-term survival of kidney transplantation. Previous studies have confirmed that macrophage…2022 American Transplant Congress
Monitoring Efficacy of Tocilizumab Treatment for Chronic Antibody Mediated Rejection (cAMR) in Kidney Transplants Using Donor-Derived Cell-Free DNA (dd-cf-DNA)
*Purpose: IL-6/IL-6R have emerged as important targets for treating cAMR. Recent data show that long-term treatment can stabilize eGFR, reduce DSAs and result in a…2022 American Transplant Congress
Donor Genetic Background Predisposes Differentiation and Accumulation of Regulatory T Cells in the Kidney Allografts
*Purpose: We have previously demonstrated that donor kidney-intrinsic innate immunity determines the severity of delayed graft function (DGF) in kidney transplantation and potentiates long kidney…2022 American Transplant Congress
Role of Innate Immunity in Regulating Host Responses to Ischemia and Reperfusion and Allograft Rejection Injury in Vascularized Composite Allotransplantation
*Purpose: Vascularized composite tissue allotransplantation (VCA) 's wide application has been impeded by deleterious side-effect of current immunosuppressive regimens. This study is aimed to determine…2022 American Transplant Congress
Rejection After Liver Transplantation: What Can We Learn from Transcriptomic Analysis?
1University of California, San Francisco, San Francisco, CA, 2UCLA, Los Angeles, CA
*Purpose: Acute cellular rejection (ACR) can occur at any time following liver transplantation (LT); initial ACR within 6 months is most common and occurs in…2022 American Transplant Congress
Diagnostic Performance of Donor-Derived Cell-Free DNA Assay (AlloSure®) in Kidney Transplant Recipients with Graft Dysfunction: A Single Center Study
*Purpose: Circulating donor-derived cell-free DNA (dd-cf-DNA) is a non-invasive biomarker of kidney allograft injury with a high negative predictive value for ruling out active rejection…2022 American Transplant Congress
Utility of Donor Derived Cell-Free DNA in Liver Transplantation
Surgery, University of Florida, Gainesville, FL
*Purpose: As a non-invasive measure of allograft injury, quantifying the fraction of donor-derived cell-free DNA (dd-cfDNA) has proven to be useful technique in kidney transplantation.…2022 American Transplant Congress
Trends in Donor Derived Cell Free DNA Before and After Cellular and Antibody Mediated Rejection
1Northwestern University, Chicago, IL, 2Transplant nephrology, Northwestern University, Chicago, IL
*Purpose: The TRAC dd-cfDNA test was developed to detect acute kidney transplant rejection but can also detect subclinical rejection with improved performance in antibody-mediated rejection…2021 American Transplant Congress
Engineered Human Glomerular Endothelial Cells to Identify Non-hla Antibodies and Decipher Their Pathogenicity After Kidney Transplantation
*Purpose: In kidney transplantation recipients (KTRs), donor-specific antibodies directed against Human Leucocyte Antigens (HLA-DSA) are thought to drive antibody-mediated rejection (AMR) and poor transplant outcome.…2021 American Transplant Congress
Validation of a Novel Gene Expression Biomarker of Rejection Following Liver Transplantation
*Purpose: Non-invasive biomarkers distinguishing early signs of immune activation vs. quiescence could more objectively guide immunosuppression management after liver transplantation (LT). Our aim was to…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 172
- Next Page »
